Taylor Hoffman Wealth Management reduced its stake in Johnson & Johnson (NYSE:JNJ) by 8.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,277 shares of the company’s stock after selling 994 shares during the period. Johnson & Johnson makes up about 1.2% of Taylor Hoffman Wealth Management’s investment portfolio, making the stock its 27th biggest holding. Taylor Hoffman Wealth Management’s holdings in Johnson & Johnson were worth $1,431,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Fisher Asset Management LLC grew its position in Johnson & Johnson by 2.6% in the second quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after purchasing an additional 301,124 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Johnson & Johnson by 0.5% in the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock worth $1,345,960,000 after purchasing an additional 48,582 shares during the period. Nordea Investment Management AB lifted its position in shares of Johnson & Johnson by 14.2% in the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after purchasing an additional 1,079,751 shares during the period. Thoroughbred Financial Services LLC lifted its position in shares of Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after acquiring an additional 3,986,071 shares during the period. Finally, Swedbank lifted its position in shares of Johnson & Johnson by 5.5% during the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after acquiring an additional 209,665 shares during the period. Institutional investors own 67.23% of the company’s stock.
Shares of JNJ stock traded down $1.02 during trading on Wednesday, hitting $128.62. The company had a trading volume of 30,426 shares, compared to its average volume of 7,262,639. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The stock’s 50-day moving average is $131.66 and its two-hundred day moving average is $136.44. The stock has a market capitalization of $337.10 billion, a price-to-earnings ratio of 15.72, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is 46.45%.
In other news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.23% of the stock is currently owned by company insiders.
JNJ has been the topic of a number of research reports. Bank of America reiterated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday. Barclays assumed coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Wells Fargo & Co restated an “outperform” rating and set a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, Credit Suisse Group set a $156.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $150.60.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: What is the downside to momentum investing?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.